Does the FDA label change mean I can't sue anymore?

No — the label change actually helps plaintiffs, not Pfizer. Before December 2025, Pfizer's central defense was called 'federal preemption' — arguing that FDA regulations prevented them from adding the warning. Once the FDA approved the warning, that defense collapsed. Courts have consistently held that plaintiffs can sue for harm that occurred before a warning was added.

Can I still file a lawsuit if I used Depo-Provera before the warning was added?

Yes, and in fact your case may be stronger precisely because you used Depo-Provera when there was no warning. The lawsuits argue that Pfizer knew about the meningioma risk for years before December 2025 and failed to warn prescribers and patients. If you were diagnosed with a meningioma after using Depo-Provera for a year or more, you may qualify regardless of when you used the drug.

What is the Pfizer preemption defense and why is it gone?

Pfizer's preemption defense argued that federal FDA regulations 'preempt' (override) state failure-to-warn claims — meaning Pfizer couldn't be sued for not warning about a risk that the FDA hadn't yet required them to disclose. When the FDA approved the meningioma warning in December 2025, it proved the agency would have permitted the warning all along, eliminating the factual basis for the preemption argument.

Home chevron_right Legal Guides chevron_right FDA Warning Label Change

FDA December 2025 warning label change for Depo-Provera medroxyprogesterone showing regulatory approval of meningioma brain tumor warning after years of Pfizer litigation

Breaking Development

FDA Finally Added a Brain Tumor Warning to Depo-Provera in December 2025 — What It Means for Your Lawsuit

Q: What did the FDA change on the Depo-Provera label in December 2025?

The FDA required Pfizer to add a warning about meningioma — a type of brain tumor — to the Depo-Provera prescribing information. The warning advises that long-term use of medroxyprogesterone acetate has been associated with an increased risk of meningioma, and recommends that prescribers consider discontinuing use in patients diagnosed with meningioma.

Dec 2025

FDA Warning Added

3,769+

Cases Now Strengthened

Preemption

Pfizer Defense Collapsed

To File Your Claim

campaign

In December 2025, the FDA required Pfizer to update Depo-Provera's label to include a meningioma brain tumor warning. This is the most significant legal development in the Depo-Provera litigation — and it helps plaintiffs, not Pfizer.

The Short Answer

The FDA's December 2025 Depo-Provera label change demolished Pfizer's primary legal defense — the argument that FDA regulations prevented Pfizer from warning women about the meningioma risk. With that defense gone, more than 3,769 pending lawsuits gained significant momentum heading into 2026 bellwether trials.

Sandra L. received her last Depo-Provera injection in 2020, after nine years of use. In early 2022, she was diagnosed with a meningioma that required surgery to remove. She filed a lawsuit in 2023. Her attorney had warned her: "Pfizer's going to say the FDA wouldn't let them warn you."

That argument — known as the preemption defense — was Pfizer's fortress. It essentially argued that because FDA regulations governed drug labeling, state-level failure-to-warn lawsuits were barred. If the FDA hadn't required the warning, Pfizer couldn't be blamed for not including one.

Then in December 2025, the FDA required the warning. The fortress collapsed. "My attorney called me the day the news broke," Sandra said. "She said, 'Pfizer just lost their best argument.'"

"When the FDA approved the warning, it proved that the agency would have permitted it years earlier — which is exactly what plaintiffs had been arguing all along." — Plaintiffs' legal strategy analysis, Depo-Provera MDL

The Timeline: From Research to Warning

2018

Early Research Links MPA to Meningioma

Preliminary European studies begin documenting elevated meningioma rates in women using progestin-only drugs including medroxyprogesterone acetate (MPA). Pfizer receives research reports.

2021

French National Cohort Study Published

A major peer-reviewed study of 108,000+ women in France finds that long-term use of injectable MPA is associated with significantly elevated meningioma risk — findings that make international medical news.

2022

BMJ Study Confirms Risk — Lawsuits Begin

The British Medical Journal publishes research confirming a 5.55x increased meningioma risk for women using MPA for one or more years. MDL formation begins in the US federal court system.

2023

MDL Established — Pfizer Asserts Preemption Defense

Federal MDL is established. Pfizer's primary defense: the FDA had not required a meningioma warning, so Pfizer cannot be liable for failing to include one. Plaintiffs argue Pfizer could and should have updated the label proactively.

Dec 2025

FDA Approves Meningioma Warning — Preemption Defense Collapses

The FDA formally requires Pfizer to add a meningioma warning to Depo-Provera's prescribing information. This action proves the FDA was willing to approve such a warning — demolishing the preemption defense. Over 3,769 pending cases are immediately strengthened.

2026

Daubert Hearing + First Bellwether Trial

A June 2026 Daubert hearing will determine whether expert testimony linking MPA to meningioma is admissible. The first bellwether trial is scheduled for December 7, 2026. Settlement negotiations are expected to accelerate.

Depo-Provera FDA warning label change timeline showing 2018 research 2021 French study 2022 BMJ confirmation 2023 MDL 2025 FDA meningioma warning and 2026 bellwether trial — From first research signals to the December 2025 FDA warning — the regulatory timeline that changed the lawsuit landscape.

Before vs. After the Label Change

Before December 2025

✗ No meningioma warning on label
✗ Pfizer's preemption defense intact
✗ Prescribers not officially informed of risk
✗ Patients using drug without awareness of brain tumor risk
✗ Pfizer arguing FDA "wouldn't have allowed" the warning

After December 2025

✓ Meningioma warning now required on label
✓ Pfizer preemption defense effectively nullified
✓ FDA action proves warning was always possible
✓ 3,769+ plaintiffs' cases significantly strengthened
✓ Settlement pressure on Pfizer increases sharply

Legal Strategy

Pfizer's Preemption Defense: Why the FDA Label Change Blew It Apart

Breaking News

The June 2026 Daubert Hearing: What It Means for Your Lawsuit

Investigative

What Pfizer Knew — and When: The 35-Year Paper Trail

Trial Update

The December 2026 Trial: What the First Verdict Means for 3,769 Cases

Frequently Asked Questions

What exactly did the FDA change on the Depo-Provera label?add

The FDA required Pfizer to add a warning about meningioma to the prescribing information. The warning advises that long-term use of medroxyprogesterone acetate has been associated with increased meningioma risk and recommends that prescribers consider discontinuing use in patients diagnosed with the condition.

Does the label change mean I can't sue?add

No — it actually helps plaintiffs. Before December 2025, Pfizer's central defense was "federal preemption" — arguing the FDA prevented them from adding the warning. When the FDA approved it, that defense collapsed. Courts have held that plaintiffs can sue for harm that occurred before a warning was added.

Can I file if I used Depo-Provera before the warning was added?add

Yes — your case may be stronger precisely because you used it when there was no warning. The lawsuits argue Pfizer knew about the risk years before December 2025 and failed to warn. If you were diagnosed with a meningioma after using Depo-Provera for a year or more, you may qualify regardless of when you used the drug.

What was Pfizer's preemption defense and why is it gone?add

Pfizer's preemption defense argued that FDA regulations prevented state-level failure-to-warn lawsuits. When the FDA approved the meningioma warning in December 2025, it proved the agency would have permitted the warning all along — eliminating the factual basis for the preemption argument.

Did Pfizer know about the meningioma risk before the FDA required the warning?add

This is the central question in the litigation. Research linking medroxyprogesterone to meningioma dates to at least 2018, with a major French study published in 2021 showing significantly elevated risk. Plaintiffs argue Pfizer was aware of emerging evidence years before the FDA required the warning and had a duty to update the label or warn prescribers sooner.

Pfizer's Best Defense Is Gone. Now Is the Time to File.

With Pfizer's preemption defense collapsed and bellwether trials scheduled for December 2026, the litigation is accelerating. If you used Depo-Provera for a year or more and were diagnosed with a meningioma, a free consultation can assess your case.

Get a Free Case Review

$0 upfront · Contingency fee only · Free evaluation